Avicanna Gestione

Gestione criteri di controllo 3/4

Avicanna Il CEO è Aras Azadian, nominato in Jan2016, e ha un mandato di 8.83 anni. la retribuzione annua totale è CA$ 336.01K, composta da 26.3% di stipendio e 73.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.01% delle azioni della società, per un valore di € 835.25K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.9 anni e 3.4 anni.

Informazioni chiave

Aras Azadian

Amministratore delegato

CA$336.0k

Compenso totale

Percentuale dello stipendio del CEO	26.3%
Mandato del CEO	8.8yrs
Proprietà del CEO	4.0%
Durata media del management	1.9yrs
Durata media del Consiglio di amministrazione	3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Aras Azadian rispetto agli utili di Avicanna?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-CA$7m
Jun 30 2024	n/a	n/a	-CA$7m
Mar 31 2024	n/a	n/a	-CA$7m
Dec 31 2023	CA$336k	CA$88k	-CA$9m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$14m
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	CA$486k	CA$161k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$16m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$15m
Dec 31 2021	CA$244k	CA$127k	-CA$17m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$29m
Mar 31 2021	n/a	n/a	-CA$34m
Dec 31 2020	CA$358k	CA$110k	-CA$33m
Sep 30 2020	n/a	n/a	-CA$25m
Jun 30 2020	n/a	n/a	-CA$24m
Mar 31 2020	n/a	n/a	-CA$21m
Dec 31 2019	CA$608k	CA$240k	-CA$22m
Sep 30 2019	n/a	n/a	-CA$18m
Jun 30 2019	n/a	n/a	-CA$14m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$150k	CA$150k	-CA$7m
Sep 30 2018	n/a	n/a	-CA$5m
Dec 31 2017	CA$180k	CA$150k	-CA$3m

Compensazione vs Mercato: La retribuzione totale di Aras ($USD 238.87K ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 474.54K ).

Compensazione vs guadagni: La retribuzione di Aras è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Aras Azadian

8.8yrs

Mandato

CA$336,008

Compensazione

Mr. Aras Azadian, M. Mgmt, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairma...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Aras Azadian	Co-Founder	8.8yrs	CA$336.01k	4.01% € 835.2k
Phillip Cardella	Chief Financial Officer	1.9yrs	CA$254.02k	0.63% € 130.4k
Ivana Maric	Executive Vice President of Marketing	no data	CA$249.08k	Nessun dato
Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	1.9yrs	CA$396.48k	Nessun dato
Karolina Urban	Executive Vice President of Scientific & Medical Affairs	1.4yrs	CA$255.87k	Nessun dato
Arash Moghani	Executive Vice President of Operations & Technology	no data	Nessun dato	Nessun dato
Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	1.4yrs	Nessun dato	Nessun dato
Enric Pujol	Vice President of People	no data	Nessun dato	Nessun dato
Carlos Enrique Muete	SVP of Clinical Development	no data	Nessun dato	Nessun dato

1.9yrs

Durata media

Gestione esperta: Il team dirigenziale di 0NN non è considerato esperto (durata media 1.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Aras Azadian	Co-Founder	8yrs	CA$336.01k	4.01% € 835.2k
Sheldon Inwentash	Member of Business Advisory Board	no data	Nessun dato	5.54% € 1.2m
Paul Fornazzari	Independent Director	less than a year	CA$12.31k	0.91% € 190.0k
Daniel Sauder	Member of Global Scientific Advisory Board	no data	Nessun dato	Nessun dato
Giancarlo Char	Director	6.1yrs	CA$88.30k	0.63% € 131.5k
Aline Masuda	Member of Business Advisory Board	no data	Nessun dato	Nessun dato
Mauricio Torres-Pradilla	Member of Global Scientific Advisory Board	no data	Nessun dato	Nessun dato
Humberto Reynales	Member of International Scientific Advisory Board	no data	Nessun dato	Nessun dato
Max Jones	Member of Global Scientific Advisory Board	no data	Nessun dato	Nessun dato
John McVicar	Independent Director	3.4yrs	CA$118.75k	0.45% € 93.0k
Eileen McCormack	Independent Director	2.8yrs	CA$110.18k	0.25% € 51.9k
Al Harrington	Member of Business Advisory Board	no data	Nessun dato	Nessun dato

3.4yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0NN sono considerati esperti (durata media dell'incarico 3.4 anni).

Avicanna Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

Less than half of directors are independent

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Insider recently bought €90k worth of stock

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought €388k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021)

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020)

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media